SCHEMBL662385

SCHEMBL662385

CCCC1CC(=O)N(Cn2c(CCl)nc3ccccc32)C1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.39
LMNA P02545 3/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 2/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
MAPT P10636 2/20 0.38
TSHR P16473 2/20 0.37
POLB P06746 1/20 0.37
KCNH2 Q12809 1/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30361183 1.00 MEN1 (0.44) MEN1KMT2AHSD17B10LMNAGAA
SCHEMBL662975 0.90 LMNA (0.48) MEN1KMT2ALMNAGAAALDH1A1
SCHEMBL2951129 0.89 LMNA (0.43) MEN1KMT2ALMNAALDH1A1TP53
SCHEMBL2951145 0.88 GLA (0.48) LMNAGAATP53KDM4E
SCHEMBL2954311 0.87 LMNA (0.48) MEN1KMT2AHSD17B10LMNATP53
SCHEMBL661009 0.87 ALDH1A1 (0.38) MEN1KMT2AHSD17B10LMNAALDH1A1
SCHEMBL1665637 0.87 LMNA (0.42) HSD17B10LMNAALDH1A1TP53RXRA
SCHEMBL17938020 0.86 KDM4E (0.47) MEN1KMT2AALDH1A1POLBMAPK1
SCHEMBL13238348 0.85 ALDH1A1 (0.41) HSD17B10ALDH1A1TP53RXRARXRB
SCHEMBL662964 0.85 ALDH1A1 (0.43) LMNAALDH1A1TP53RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763644-B2 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2010-07-27 US claimed
EP-2050736-A1 Imidazole derivatives, processes for preparing them and their uses UCB Pharma, S.A. (BE) 2009-04-22 EP claimed
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. 2008-04-03 US claimed
JP-2007513105-A 2007-05-24 JP claimed
CN-1906160-A Imidazole derivatives, processes for preparing them and their uses UCB SA (BE) 2007-01-31 CN claimed
EP-1706376-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-10-04 EP claimed
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2005-06-23 US claimed
WO-2005054188-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-06-16 WO claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2010-04-22 US disclosed
EP-2050736-A1 Imidazole derivatives, processes for preparing them and their uses UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. 2008-04-03 US disclosed
US-7244747-B2 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-07-17 US disclosed
CN-1906160-A Imidazole derivatives, processes for preparing them and their uses UCB SA (BE) 2007-01-31 CN disclosed
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A MEN1 4306/4885KMT2A 530/4885HSD17B10 2514/4885
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 MEN1 4554/4885KMT2A 116/4885HSD17B10 2745/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 MEN1 4554/4885KMT2A 116/4885HSD17B10 2745/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 MEN1 4554/4885KMT2A 116/4885HSD17B10 2745/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 MEN1 3878/4885KMT2A 140/4885HSD17B10 929/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE MEN1 4285/4885KMT2A 793/4885HSD17B10 1998/4885
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses CYP3A4, PPIP5K2, CYP2C19 MEN1 1047/4885KMT2A 1901/4885HSD17B10 3398/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 MEN1 3438/4885KMT2A 478/4885HSD17B10 1789/4885
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses CYP3A4, PPIP5K2, CYP2C19 MEN1 1047/4885KMT2A 1901/4885HSD17B10 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.